Liposomes as Drug Delivery System: A Strategic Approach for the Treatment of HIV Infection

References

• Allen T. M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Res 1994a; 15: 215–220
   PubMed Web of Science ®Google Scholar
• Allen T. M. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv. Drug Deliv. Rev 1994b; 13: 285–309
   Web of Science ®Google Scholar
• Allen T. M. Liposomal drug delivery. Curr. Opin. Colloid & Interf. Sci 1996; 1: 645–651
   Web of Science ®Google Scholar
• Allen T. M., Hansen C. B., Guo L. S. S. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta 1993; 1150: 9–16
   PubMed Web of Science ®Google Scholar
• Allen T. M., Moase E. H. Therapeutic opportunities for targeted liposomal drug delivery. Adv. Drug Deliver. Rev 1996; 21: 117–123
   Web of Science ®Google Scholar
• Aloia R. C., Jensen F. C., Curtain C. C., Mobley P. W., Gordon L. M. Lipid composition and fluidity of the human immunodeficiency virus. Proc. Nail. Acad. Sci. USA 1988; 85: 900–904
   PubMed Web of Science ®Google Scholar
• Anazodo M. I., Wainberg M. A., Friesen A. D., Wright J. A. Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome. J. Virol 1995; 69: 1794–1801
   PubMed Web of Science ®Google Scholar
• Bakker-Woudenberg I. A. J. M. Liposomes in the treatment of parasitic, viral, fungal and bacterial infections. J. Lipos. Res 1995; 5: 169–191
   Google Scholar
• Bangham A. D., Standish M. M., Watkins J. C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol 1965; 13: 238–252
   PubMed Web of Science ®Google Scholar
• Betageri G. V. Liposomal encapsulation and stability of dideoxyinosine triphosphate. Drug Developm. Indust. Pharm 1993; 19: 531–539
   Web of Science ®Google Scholar
• Betageri G. V., Black C. D. V., Szebeni J., Wahl L. M., Weinstein J. N. Fc-receptor-mediated targeting of antibody-bearing liposomes containing dideoxycytidine triphosphate to human monocyte/macrophages. J. Pharm. Pharmacol 1993a; 45: 48–53
   PubMed Web of Science ®Google Scholar
• Betageri G. V., Jenkins S. A., Ravis W. R. Drug delivery using antibody-liposome conjugates. Drug Dev. Ind. Pharm 1993b; 19: 2109–2116
   Web of Science ®Google Scholar
• Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties?. Bioehim. Biophys. Acta 1986; 864: 257–304
   PubMed Web of Science ®Google Scholar
• Bryant M. L., Heuckeroth R. O., Kimata J. T., Ratner L., Gordon J. I. Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid. Proc. Natl. Acad. Sci. USA 1989; 86: 8655–8659
   PubMed Web of Science ®Google Scholar
• Bryant M. L., Ratner L., Duronio R. J., Kishore N. S., Devadas B., Adams S. P., Gordon J. I. Incorporation of 12-methoxydodecanoate into the human immunodeficiency virus 1 gag polyprotein inhibits its proteolytic processing and virus production in a chronically infected human lymphoid cell line. Proc. Natl. Acad. Sci. USA 1991; 88: 2055–2059
   PubMed Web of Science ®Google Scholar
• Cavert W., Notermans D. W., Staskus K., Wietgrefe S. W., Zupancic M., Gebhard K., Henry K., Zhang Z. Q., Mills R., McDade H., Goudsmith J., Danner S. A., Haase A. T. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276: 960–964
   PubMed Web of Science ®Google Scholar
• Chen D., Lee K. H. Biodistribution of calcitonin encapsulated in liposomes in mice with particular reference to the central nervous system. Bioehim. Biophys. Acta 1993; 1158: 244–250
   PubMed Web of Science ®Google Scholar
• Chonn A., Cullis P. R. Recent advances in liposomal drug-delivery systems. Curr. Opin. Biotechnoi 1995; 6: 698–708
   PubMed Web of Science ®Google Scholar
• Chrisp P., Clissold P. Foscarnet: A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991; 41: 104–129
   PubMed Web of Science ®Google Scholar
• Chu C., Szoka F., Jr. Antiviral activity and pharmacokinetics of liposome-encapsulated phosphonofor-mate in Rauscher murine leukemia virus-infected-mice. J. Lipos. Res 1992; 2: 67–92
   Google Scholar
• Compagnon B., Milhaud P., Bienvenue A., Philippot J. R. Targeting of poly(rI)-poly(rC) by fusogenic (F protein) immunoliposomes. Exp. Cell Res 1992; 200: 333–338
   PubMed Web of Science ®Google Scholar
• Cudd A., Noonan C. A., Tosi P. F., Melnick J. L., Nicolau C. Specific interaction of CD4-bearing liposomes with HIV-infected cells. J. Acquir. Immune Defic. Syndr 1990; 3: 109–114
   PubMed Web of Science ®Google Scholar
• Désormeaux A., Harvie P., Perron S., Makabi-Panzu B., Beauchamp D., Tremblay M., Poulin L., Bergeron M. G. Antiviral efficacy, intracellular uptake and tissue distribution of liposome-encapsulated 2',3'-dideoxyinosine (ddl) in rats. AIDS 1994; 8: 1545–1553
   PubMed Web of Science ®Google Scholar
• Deutsch G., Phillips N. C., Tsoukas CM. Lipo-somal-azidothymidine (AZT) in advanced HIV disease: A phase I study. Can. J. Infect. Dis 1993; 4(suppl. B)27B
   Google Scholar
• Dipali S. R., Lin Y. J., Ravis W. R., Betageri G. V. Pharmacokinetics and tissue distribution of long circulating liposomal formulation of 2',3'-dideoxyinosine. Int. J. Pharm 1997; 152: 89–97
   Web of Science ®Google Scholar
• Dusserre N., Lessard C., Paquette N., Perron S., Poulin L., Tremblay M., Beauchamp D., Desormeaux A., Bergeron M. G. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution, and pharmacokinetics. AIDS 1995; 9: 833–841
   PubMed Web of Science ®Google Scholar
• Düzgünes N., Flasher D., Chamow S., Dazin P., Konopka K. Liposome targeting to HIV-infected cells via recombinant soluble CD4 and CD4-IgG (immuno-adhesin). J. Cell. Biochem 1992; 16E: 77, Suppl.
   Google Scholar
• Embretson J., Zupancic M., Ribas J. L., Burke A., Racz P., Tenner-Racz K., Haase A. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 359–362
   PubMed Web of Science ®Google Scholar
• Fauci A. S. Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 1993; 262: 1011–1017
   PubMed Web of Science ®Google Scholar
• Feigner P. L., Gadek T. R., Holm M., Roman R., Chan H. W., Wenz M., Northrop J. P., Ringold G. M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 1987; 84: 7413–7417
   PubMed Web of Science ®Google Scholar
• Flasher D., Konopka K., Chamow S. M., Dazin P., Ashkenazi A., Pretzer E., Düzgünes N. Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG). Biochim. Biophys. Acta 1994; 1194: 185–196
   PubMed Web of Science ®Google Scholar
• Fox C. H., Hoover S., Curral V. R., Bahre H. J., Cottier-Fox M. HIV in infected lymph nodes. Nature 1994; 370: 256
   PubMed Web of Science ®Google Scholar
• Fox C. H., Tenner-Rácz K., Rácz P., Firpo A., Pizzo P. A., Fauci A. S. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J. Infect. Dis 1991; 164: 1051–1057
   PubMed Web of Science ®Google Scholar
• Gangemi J. D., Nachtigal M., Barnhart D., Krech L., Jani P. Therapeutic efficacy of liposome-encapsulated ribavirin and muramyl tripeptide in experimental infection with influenza or herpes simplex virus. J. Infect. Dis 1987; 155: 510–517
   PubMed Web of Science ®Google Scholar
• Gendelman H. E., Orenstein J. M., Baca L. M., Weiser B., Burger H., Kalter D. C., Meltzer M. S. The macrophage in the persistence and pathogenesis of HIV infection. AIDS 1989; 3: 475–495
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Overview of liposomes. J. Antimicrob. Chemother 1991; 28: 39–48
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol 1995; 13: 527–537
   PubMed Web of Science ®Google Scholar
• Harvie P., Désormeaux A., Bergeron M. C., Tremblay M., Beauchamp D., Poulin L., Bergeron M. G. Comparative pharmacokinetics, distribution in tissues, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine. Antimicrob. Agents Chemother 1996; 40: 225–229
   PubMed Web of Science ®Google Scholar
• Harvie P., Désormeaux A., Gagné N., Tremblay M., Poulin L., Beauchamp D., Bergeron M. G. Lymphoid tissues targeting of liposome-encapsulated 2',3'-dideoxyino-sine (ddI). AIDS 1995; 9: 701–707
   PubMed Web of Science ®Google Scholar
• Heath S. L., Grant Tew J., Tew J. G., Szakal A. K., Burton G. F. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995; 377: 740–744
   PubMed Web of Science ®Google Scholar
• Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123–126
   PubMed Web of Science ®Google Scholar
• Ho R. J., Burke R. L., Merigan T. C. Physical and biological characterization of antigen presenting liposome formulations: relative efficacy for the treatment of recurrent genital HSV-2 in guinea pigs. Antivir. Res 1990; 13: 187–200
   PubMed Web of Science ®Google Scholar
• Ho R. J. Y., Burke R. L., Merigan T. C. Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs. J. Virol 1989; 63: 2951–2958
   PubMed Web of Science ®Google Scholar
• Ho R. J. Y., Rouse B. T., Huang L. Interactions of target-sensitive immunoliposomes with herpes simplex virus. J. Biol. Chem 1987a; 262: 13979–13984
   PubMed Web of Science ®Google Scholar
• Ho R. J. Y., Rouse B. T., Huang L. Target-sensitive immunoliposomes as an efficient drug carrier for antiviral activity. J. Biol. Chem 1987b; 262: 13973–13978
   PubMed Web of Science ®Google Scholar
• Hostetler K. Y., Richman D. D., Sridhar C. N., Feigner P. L., Feigner J., Ricci J., Gardner M. F., Selleseth D. W., Ellis M. N. Phosphatidylazidothymidine and phospha-tidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice. Antimicrob. Agents Chemother 1994; 38: 2792–2797
   PubMed Web of Science ®Google Scholar
• Hostetler K. Y., Stuhmiller L. M., Lenting H. B. M., van den Bosch H., Richman D. D. Synthesis and anti-retroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides. J. Biol. Chem 1990; 265: 6112–6117
   PubMed Web of Science ®Google Scholar
• Huwyler J., Wu D., Pardridge W. M. Brain drug delivery of small molecules using immunoliposomes. Proc. Nat. Acad. Sci. USA 1996; 93: 14164–14169
   PubMed Web of Science ®Google Scholar
• Ikuta K., Ueda S., Uchida T., Okada Y., Kato S. Selective killing of human immunodeficiency virus-infected and -producing cells by liposomes containing diphtheria toxin fragment A. Jpn J. Cancer Res 1987; 78: 1159–1163
   PubMedGoogle Scholar
• Jacobson M. Review of the toxicities of foscarnet. J. Acquir. Immune Defic. Syndr 1992; 5(suppl.l)S11–S17
   PubMedGoogle Scholar
• Jolicoeur P. Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. FASEB 1991; 5: 2398–2405
   PubMed Web of Science ®Google Scholar
• Kamps J. A. A. M., Swart P. J., Morselt H. W., Pauwels R., De Bethune M. P., De Clercq E., Meijer D. K., Scherphof G. L. Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity. Biochim. Biophys. Acta 1996; 1278: 183–90
   PubMed Web of Science ®Google Scholar
• Kim C. K., Choi Y. J., Lim S. J., Lee M. G., Lee S. H., Hwang S. J. Lymph node targeting and pharmacokinetics of [3H]methotrexate-encapsulated neutral large unilamellar vesicles and immunoliposomes. Int. J. Pharm 1993; 98: 9–18
   Google Scholar
• Kim C. K., Han J. H. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged Iposome-entrapped methotrexate to rats. J. Microencapsulation 1995; 12: 437–446
   PubMed Web of Science ®Google Scholar
• Kim S., Scheerer S., Geyer M. A., Howell S. B. Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes. J. Infect. Dis 1990; 162: 750–752
   PubMed Web of Science ®Google Scholar
• Koch J. A., Ruprecht R. M. Animal models for anti-AIDS therapy. Antivir. Res 1992; 19: 81–109
   PubMed Web of Science ®Google Scholar
• Koff W. C., Fidler I. J., Showalter S. D., Chakrabarty M. K., Hampar B., Ceccorulli L. M., Kleinerman E. S. Human monocytes activated by immunomodulators in liposomes lyse herpes virus-infected but not normal cells. Science 1984; 224: 1007–1009
   PubMed Web of Science ®Google Scholar
• Koff W. C., Showalter S. D., Hampar B., Fidler I. J. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide. Science 1985; 228: 495–497
   PubMed Web of Science ®Google Scholar
• Konopka K., Davis B. R., Larsen C. E., Alford D. R., Debs R. J., Düzgünes N. Liposomes modulate human immunodeficiency virus infectivity. J. Gen. Virol 1990; 71: 2899–2907
   PubMed Web of Science ®Google Scholar
• Konopka K., Pretzer E., Plowman B., Düzgünes N. Long-term noncytopathic productive infection of the human monocytic leukemia cell line THP-1 by human immunodeficiency virus type 1 (HIV-1 me). Virology 1993; 193: 877–887
   PubMed Web of Science ®Google Scholar
• Konopka K., Stamatatos L., Larsen C. A., Davis B. R., Düzgünes N. Enhancement of human immunodeficiency virus type 1 infection by cationic liposomes: The role of CD4, serum and liposome-cell interactions. J. Gen. Virol 1991; 72: 2685–2696
   PubMed Web of Science ®Google Scholar
• Kumagai K., Nabeshima S., Kato S., Watanabe M., Ikuta K. Selective killing of HIV-infected cells by liposomes composed of dimyristoylphosphatidylcholine/ phosphatidyl-serine/cholesterol. Antiv. Chem. Chemother 1991; 2: 143–148
   Google Scholar
• Larsen C. E., Alford D. R., Young L. J. T., McGraw T. P., Düzgünes N. Fusion of simian immunodeficiency virus with liposomes and erythrocyte ghost membranes: effects of lipid composition, pH and calcium. J. Gen. Virol 1990; 71: 1947–1955
   PubMed Web of Science ®Google Scholar
• Larsen C. E., Nir S., Alford D. R., Jennings M., Lee K. D., Düzgünes N. Human immunodeficiency virus type 1 (HIV-1) fusion with model membranes: kinetic analysis and the role of lipid composition, pH and divalent cations. Biochim. Biophys. Acta 1993; 1147: 223–236
   PubMed Web of Science ®Google Scholar
• Lasic D. D. Liposomes: From Physics to Applications. Elsevier, Amsterdam 1993
   Google Scholar
• Lazdins J. K., Woods-Cook K., Walker M., Alteri E. The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages. AIDS Res. Hum. Retroviruses 1990; 6: 1157–1161
   PubMed Web of Science ®Google Scholar
• Leonetti J. P., Degols G., Clarenc J. P., Mechti N., Lebleu B. Cell delivery and mechanisms of action of antisense oligonucleotides. Prog. Nucleic Acid Res. Mol. Biol 1993; 44: 143–167
   PubMed Web of Science ®Google Scholar
• Lynn W. S., Tweedale A., Cloyd M. W. Human immunodeficiency virus (HIV-1) cytotoxicity: perturbation of the cell membrane and depression of phospholipid synthesis. Virology 1988; 163: 43–51
   PubMed Web of Science ®Google Scholar
• Makabi-Panzu B., Lessard C., Beauchamp D., Désormeaux A., Poulin L., Tremblay M., Bergeron M. G. Uptake and binding of liposomal 2',3'-dideoxycytidine by RAW 264.7 cells: a three-step process. J. Acquir. Immune Defw. Syndr. Hum. Retrovirol 1995; 8: 227–235
   PubMedGoogle Scholar
• Makabi-Panzu B., Lessard C., Perron S., Desormeaux A., Tremblay M., Poulin L., Beauchamp D., Bergeron M. G. Comparison of cellular accumulation, tissue distribution and anti-HIV activity of free and liposomal 2',3'-dideoxycytidine. AIDS Res. Hum. Retroviruses 1994; 10: 1463–1470
   PubMed Web of Science ®Google Scholar
• Manouilov K. K., Fedorov I. I., Boudinot F. D., White C. A., Kotra L. P., Schinazi R. F., Hong C., Chu C. K. Lymphatic targeting of anti-HIV nucleosides: distribution of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2'-3'-dideoyuridine (AZdU) after administration of dipalmitoyl-phosphatidyl prodrugs to mice. Antivir. Chem. Chemother 1995; 6: 230–238
   Web of Science ®Google Scholar
• Morse H. C., III, Chattopadhyay S. K., Makino M., Fredrickson T. N., Hiigin A. W., Hartley J. W. Retrovirus-induced immunodeficiency in the mouse: Maids as a model for AIDS. AIDS 1992; 6: 607–621
   PubMed Web of Science ®Google Scholar
• Müller W. E. G., Weiler B. E., Charubala R., Pfleiderer W., Leserman L., Sobol R. W., Suhadolnik R. J., Schröder H. C. Cordycepin analogues of 2',5'-oligoadenylate inhibit human immunodeficiency virus infection via inhibition of reverse transcriptase. Biochemistry 1991; 30: 2027–2033
   PubMed Web of Science ®Google Scholar
• Nässander U. K., Storm G., Peeters P. A. M., Crommelin D. J. A. Liposomes. Biodegradable Polymers as Drug Delivery Systems, M. Chasin, R. Langer. Marcel Dekker, Inc., New York 1990; 261–338
   Google Scholar
• Okada J., Cohen S., Langer R. In vitro evaluation of polymerized liposomes as an oral drug delivery system. Pharm. Res 1995; 12: 576–582
   PubMed Web of Science ®Google Scholar
• Omar R., Dusserre N., Desormeaux A., Poulin L., Tremblay M., Beauchamp D., Bergeron M. G. Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Antimicrob. Agents Chemother 1995; 39: 1973–1978
   PubMed Web of Science ®Google Scholar
• Pantaleo G., Graziosi C., Demarest J. F., Butini L., Montoni M., Fox C. H., Orenstein J. M., Kotler D. P., Fauci A. S. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355–358
   PubMed Web of Science ®Google Scholar
• Phillips N. C., Emili A. Immunogenicity of immuno-liposomes. Immunol. Lett 1991; 30: 291–296
   PubMed Web of Science ®Google Scholar
• Phillips N. C., Gagne L., Tsoukas C., Dahman J. Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status. J. Immunol 1994; 152: 3168–3174
   PubMed Web of Science ®Google Scholar
• Phillips N. C., Skamene E., Tsoukas C. Liposomal encapsulation of 3'-azido-3'-deoxythymidine (AZT) results in decreased bone marrow toxicity and enhanced activity against murine AIDS-induced immunosuppression. J. Acquir. Immune Defic. Syndr 1991; 4: 959–966
   PubMed Web of Science ®Google Scholar
• Phillips N. C., Tsoukas C. Immunoliposome targeting to CD4+ cells in human blood. Cancer Detect. Prev 1990; 14: 383–390
   PubMedGoogle Scholar
• Phillips N. C., Tsoukas C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 1992; 79: 1137–1143
   PubMed Web of Science ®Google Scholar
• Pidgeon C., Markovich R. J., Liu M. D., Holzer T. J., Novak R. M., Keyer K. A. Antiviral phospholipids. Anti-HIV drugs conjugated to the glycerobackbone of phospholipids. J. Biol. Chem 1993; 268: 7773–7778
   PubMed Web of Science ®Google Scholar
• Pizzati A., Ledda A., Rombi G., Piu G., Piro S., Contu L. In vitro inhibitory effect of zidovudine encapsulated in liposomes on the lymphoproliferative response. Med. Sci. Res 1994; 22: 467–470
   Google Scholar
• Pontani D. R., Sun D., Brown J. W., Shahied S. I., Plescia O. J., Schaffner C. P., Lopez-Berenstein G., Sarin P. S. Inhibition of HIV replication by liposomal encapsulated amphotericin B. Anlivir. Res 1989; 11: 119–126
   PubMed Web of Science ®Google Scholar
• Puyal C., Milhaud P., Bienvenue A., Philippot J. R. A new cationic liposome encapsulating genetic material. A potential delivery system for polynucleotides. Eur. J. Biochem 1995; 228: 697–703
   PubMedGoogle Scholar
• Renneisen K., Leserman L., Matthes E., Schröder H. C., Müller W. E. Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the env region. J. Biol. Chem 1990; 265: 16337–16342
   PubMed Web of Science ®Google Scholar
• Rios A., Rosemblum M., Crofoot G., Lenk R. P., Hayman A., Lopez-Berenstein G. Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection. J. Infect. Dis 1993; 168: 253–254
   PubMed Web of Science ®Google Scholar
• Schaffner C. P., Plescia O. J., Pontani D., Sun D., Thornton A., Pandey R. S., Sarin P. Antiviral activity of amphotericin B methyl ester: Inhibition of Htlv-III replication in cell culture. Biochem. Pharmacol 1986; 35: 4110–4113
   PubMed Web of Science ®Google Scholar
• Schott H., Haussler M. P., Gowland P., Bender A., von Briesen H., Schwendener R. A. Synthesis and in vitro antiviral properties of amphiphilic dinucleoside phosphate derivatives of 2',3'-dideoxycytidine (ddC). Anlivir. Chem. Chemother 1995; 6: 320–326
   Web of Science ®Google Scholar
• Schrager L. K., Fauci A. S. Trapped but still dangerous. Nature 1995; 377: 680–681
   PubMed Web of Science ®Google Scholar
• Sechoy O., Vidal M., Philippot J. R., Bienvenue A. Interactions of human lymphobtasts with targeted vesicles containing Sendai virus envelope proteins. Exp. Cell Res 1989; 185: 122–131
   PubMed Web of Science ®Google Scholar
• Selvam M. P., Blay R. A., Geyer S., Buck S. M., Pollock L., Mayner R. E., Epstein J. S. Inhibition of HIV-1 replication in H9 cells by Nystatin-A compared with other antiviral agents. AIDS Res. Human Retroviruses 1993; 9: 475–481
   PubMed Web of Science ®Google Scholar
• Selvam M. P., Buck S. M., Blay R. A., Maayner R. E., Mied P. A., Epstein J. S. Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. Antiv. Res 1996; 33: 11–20
   PubMed Web of Science ®Google Scholar
• Steim J. M., Camaioni Neto C., Sarin P. S., Sun D. K., Sehgal R. K., Turcotte J. G. Lipid conjugates of anti-retroviral agents. I. Azidothymidine-monophosphate-digly-ceride: anti-HIV activity, physical properties, and interaction with plasma proteins. Biochem. Biophvs. Res. Commun 1990; 171: 451–457
   PubMed Web of Science ®Google Scholar
• Sullivan S. M., Gieseler R. K. U., Lenzner S., Ruppert J., Gabrysiak T. G., Peters J. H., Cox G., Richer L., Martin W. J., Scolaro M. J. Inhibition of human immunodeficiency virus-1 proliferation by liposome-encapsulated sense DNA to the 5'TAT splice acceptor site. Antisense Res. Dev 1992; 2: 187–197
   PubMedGoogle Scholar
• Sullivan S. M., Huang L. Enhanced delivery to target cells by heat-sensitive immunoliposomes. Proc. Natl. Acad. Sci. USA 1986; 83: 6117–6121
   PubMed Web of Science ®Google Scholar
• Szebeni J., Wahl S. M., Betageri G. V., Wahl L. M., Gartner S., Popovic M., Parker R. J., Black C. D. V., Weinstein J. N. Inhibition of HIV-1 in monocyte/macrophage cultures by 2',3'-dideoxycytidine-5'-triphosphate, free and in liposomes. AIDS Res. Hum. Retroviruses 1990; 6: 691–702
   PubMed Web of Science ®Google Scholar
• Szoka F. C., Jr. The future of liposomal drug delivery. Biotechnol. Appl. Biochem 1990; 12: 496–500
   PubMed Web of Science ®Google Scholar
• Thibodeau L., Chagnon M., Flamand L., Oth D., Lachapelle L., Tremblay C., Montagnier L. Ro˘le des liposomes dans la présentation de la glycoprotéine de l'enveloppe du VIH et la réponse immunitaire chez la souris. C. R. Acad. Sci 1989; 309: 741–747
   PubMedGoogle Scholar
• Velinova M., Read N., Kirby C., Gregoriadis G. Morphological observations on the fate of liposomes in the regional lymph nodes after footpad injection into rats. Biochim. Biophys. Acta 1996; 1299: 207–215
   PubMed Web of Science ®Google Scholar
• Wasan K. M., Lopez-Berenstein G. The past, present, and future uses of liposomes in treating infectious diseases. Immunopharmacol. Immunotoxicol 1995; 17: 1–15
   PubMed Web of Science ®Google Scholar
• Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H., Saag M. S., Shaw G. M. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 313: 117–122
   Google Scholar
• Woodle M. C., Lasic D. D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992; 1113: 171–199
   PubMed Web of Science ®Google Scholar
• Xu Y., Szoka F. C., Jr. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfec-tion. Biochemistry 1996; 35: 5616–5623
   PubMed Web of Science ®Google Scholar
• Zelphati O., Degols G., Loughrey H., Leserman L., Pompon A., Puech F., Maggio A. F., Imbach J. L., Gosselin G. Inhibition of HIV-1 replication in cultured cells with phosphorylated dideoxyuridine derivatives encapsulated in immunoliposomes. Antivir. Res 1993a; 21: 181–95
   PubMed Web of Science ®Google Scholar
• Zelphati O., Imbach J. L., Signoret N., Zon G., Rayner B., Leserman L. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res 1994a; 22: 4307–4314
   PubMed Web of Science ®Google Scholar
• Zelphati O., Wagner E., Leserman L. Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodi-ester antisense oligonucleotides incorporated into immunoliposomes. Antiviral Res 1994b; 25: 13–25
   PubMed Web of Science ®Google Scholar
• Zelphati O., Zon G., Leserman L. Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. Antisense Res. Dev 1993b; 3: 323–38
   PubMedGoogle Scholar